Sunscreen products: Rationale for use, formulation development and regulatory considerations

被引:63
|
作者
Geoffrey, Kiriiri [1 ]
Mwangi, A. N. [1 ]
Maru, S. M. [1 ]
机构
[1] Univ Nairobi, Sch Pharm, Dept Pharmaceut & Pharm Practice, POB 19676-00202, Nairobi, Kenya
关键词
Sunscreens; Photoprotection; Ultraviolet rays; UVA; UVB; Sun protection factor (SPF); Water resistance; Minimum erythemal dose (MED); SKIN-CANCER; ULTRAVIOLET-RADIATION; PROTECTION FACTORS; SUN EXPOSURE; LIGHT; PREVENTION; EFFICACY;
D O I
10.1016/j.jsps.2019.08.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The association of sunrays with skin damage have been known since medieval times. The description of the electromagnetic spectrum facilitated the identification of the ultraviolet light spectrum as being responsible for skin damage resulting from prolonged skin exposure. Sunscreens have been used since ancient civilizations with various measures to limit exposure to sun exposure being employed. Awareness of the risks associated with sunrays has been increasing in the last century, and as a result, the science, technologies, and formulation have advanced significantly. The use of sunscreen products continues rising as government health agencies seek to contain increasing cases of UV induced melanomas. Recreational sunbathing and artificial tanning have increased the risk for these diseases significantly. This review article sought to expound the scientific basis of sunscreen use, the classification, formulation, quality control and regulation across the different countries around the world. The literature review was conducted on Google scholar, PubMed, SCOPUS, Cochrane, BMJ, SCIELO among others. (C) 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:1009 / 1018
页数:10
相关论文
共 50 条
  • [1] Rationale for sunscreen development
    Forestier, Serge
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (05) : S133 - S138
  • [2] FDA considerations for sunscreen safety and efficacy: Sunscreen products.
    Brown, PC
    Jacobs, A
    Lipnicki, JD
    Wilkin, JK
    [J]. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1999, 69 : 52S - 53S
  • [3] Key considerations in formulation development for gene therapy products
    Mohammad, Rafi
    [J]. DRUG DISCOVERY TODAY, 2022, 27 (01) : 292 - 303
  • [4] Component, Formulation and Regulatory of Sunscreen Materials: A Brief Review
    Hariani, Firi Oktavia
    Jerusalem, Mohammad Adam
    Tahir, Iqmal
    Utami, Maisari
    Oh, Won-Chun
    Wijaya, Karna
    [J]. KOREAN JOURNAL OF MATERIALS RESEARCH, 2023, 33 (03): : 87 - 94
  • [5] Regulatory considerations for rapid development of biological products.
    Swann, PG
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U212 - U212
  • [6] Regulatory considerations for development of bioanalytical assays for biotechnology products
    Swann, Patrick G.
    Shapiro, Marjorie A.
    [J]. BIOANALYSIS, 2011, 3 (06) : 597 - 603
  • [7] An expanding horizon of complex injectable products: development and regulatory considerations
    Panchal, Kanan
    Katke, Sumeet
    Dash, Sanat Kumar
    Gaur, Ankit
    Shinde, Aishwarya
    Saha, Nithun
    Mehra, Neelesh Kumar
    Chaurasiya, Akash
    [J]. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2023, 13 (02) : 433 - 472
  • [8] An expanding horizon of complex injectable products: development and regulatory considerations
    Kanan Panchal
    Sumeet Katke
    Sanat Kumar Dash
    Ankit Gaur
    Aishwarya Shinde
    Nithun Saha
    Neelesh Kumar Mehra
    Akash Chaurasiya
    [J]. Drug Delivery and Translational Research, 2023, 13 : 433 - 472
  • [9] Practical, regulatory and clinical considerations for development of inhalation drug products
    Hou, Shuguang
    Wu, Jiangyue
    Li, Xu
    Shu, Hong
    [J]. ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 10 (06) : 490 - 500
  • [10] Rationale and strategies for formulation development of oral fixed dose combination drug products
    Moon C.
    Oh E.
    [J]. Journal of Pharmaceutical Investigation, 2016, 46 (7) : 615 - 631